Network Meta-analysis of oral blood-activating and stasis-removing Chinese patent medicines in treatment of hypertensive left ventricular hypertrophy.
10.19540/j.cnki.cjcmm.20211214.501
- Author:
Ya-Wei ZHENG
1
;
Jie LI
2
;
Wen-Qiang YAO
1
;
Ming-Yao PAN
1
;
Yuan FANG
2
Author Information
1. Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, China Nanjing University of Chinese Medicine Nanjing 210023, China.
2. Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, China Jiangsu Province Hospital of Chinese Medicine Nanjing 210029, China.
- Publication Type:Meta-Analysis
- Keywords:
Chinese patent medicine;
blood-activating and stasis-removing;
hypertension;
left ventricular hypertrophy(LVH);
network Meta-analysis
- MeSH:
China;
Humans;
Hypertrophy, Left Ventricular/drug therapy*;
Medicine, Chinese Traditional;
Network Meta-Analysis;
Nonprescription Drugs;
Stroke Volume;
Ventricular Function, Left
- From:
China Journal of Chinese Materia Medica
2022;47(5):1383-1391
- CountryChina
- Language:Chinese
-
Abstract:
This study was designed to assess the clinical efficacy of oral blood-activating and stasis-removing Chinese patent medicines in treating hypertensive left ventricular hypertrophy(LVH) based on network Meta-analysis. The clinical randomized controlled trials(RCTs) concerning the treatment of hypertensive LVH with oral blood-activating and stasis-removing Chinese patent medicines were retrieved from CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, and Cochrane Library from their inception to September 2021. Two researchers independently completed the literature screening, data extraction, and quality evaluation. The data were then analyzed by RevMan 5.3, Stata 15.1, and ADDIS 1.16.8. Finally, a total of 31 RCTs were included, involving 3 001 patients and four oral blood-activating and stasis-removing Chinese patent medicines. In terms of the alleviation of heart damage, the Chinese patent medicines combined with conventional western medicine groups were superior to the conventional western medicine groups in lo-wering the left ventricular mass index(LVMI). There was no significant difference in LVMI, left ventricular ejection fraction(LVEF), or the ratio of early diastolic peak flow velocity to late diastolic peak flow velocity(E/A) between different Chinese patent medicines combined with conventional western medicine groups. Xinnao Shutong Capsules/Tablets combined with conventional western medicine had the best efficacy in reducing LVMI and elevating LVEF, while Xinkeshu Capsules/Tablets combined with conventional western medicine had the best effect in improving E/A. In the control of blood pressure, when all Chinese patent medicines except for Xinnao Shutong Capsules/Tablets were combined with conventional western medicine, the resulting systolic blood pressure(SBP) and diastolic blood pressure(DBP) were significantly lower than those in the conventional western medicine group. Xinkeshu Capsules/Tablets combined with conventional western medicine produced the best effect in reducing SBP and DBP, followed by Xinnao Shutong Capsules/Tablets. In terms of safety, no serious adverse reactions occurred in all trials. The four oral blood-activating and stasis-removing Chinese patent medicines included in this study exhibited obvious advantages in the treatment of hypertensive LVH when they were combined with conventional western medicine, with the best effects observed in the Xinnao Shutong Capsules/Tablets combined with conventional western medicine group. However, due to the limitation of the quantity and quality of the included articles, the conclusion of this study still needs to be verified by more high-quality, multi-center, and large-sample RCTs.
